Rankings
▼
Calendar
URGN Q1 2016 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$918M
Q1 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$4M
Net Income
-$4M
EPS (Diluted)
$-1.81
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$440,000
Balance Sheet
Total Assets
$18M
Total Liabilities
$3M
Stockholders' Equity
$14M
Cash & Equivalents
$15M
← FY 2016
All Quarters
Q2 2016 →